Hippocratic AI, Inc.

Founded in 2023 in Palo Alto, US, Hippocratic AI, Inc. , trading under the name Hippocratic AI develops AI-driven tools for healthcare providers. In November 2025, Hippocratic AI raised USD 126 million in series C funding led by Avenir Growth Capital, with participation from Kleiner Perkins, CapitalG, General Catalyst Partners, Universal Health Services, Cincinnati Children's Hospital Medical Center, Andreessen Horowitz, and WellSpan Health. CEO Shae Mclaughlin leads the company, current valuation of USD 3,500 mn.

Hippocratic AI specializes in advanced artificial intelligence solutions for the healthcare sector, focusing on enhancing patient care. Their core offering is an AI agent designed to recognize subtle symptoms and escalate care as needed, thereby facilitating early medical intervention. The AI employs a novel architecture, utilizing over 4. 1 trillion parameters, which allows it to cross-analyze patient conditions, medications, and personal descriptions to identify appropriate treatments effectively.

The technology has been clinically validated, ensuring its accuracy and safety in real-world applications. Targeted end-use cases include improving colorectal cancer screening rates and engaging Spanish-speaking populations, showcasing its commitment to closing care gaps. The company primarily serves healthcare providers and organizations across North America and Latin America. Hippocratic AI's revenue model centers around partnerships and subscriptions with healthcare organizations that utilize its AI solutions.

Clients, which include hospitals and clinics, integrate the AI agent into their operational workflows, allowing them to enhance staff efficiency by reallocating tasks to the AI, thus reducing clinician workload. Transactions occur as healthcare providers pay for ongoing access to the AI service, enabling continuous updates and improvements in functionality. While specific pricing structures are not disclosed, the revenue is generated from long-term contracts that provide clients with tailored AI solutions to improve patient engagement and outcomes over time. In November 2025, Hippocratic AI raised USD 126 mn in Series C funding to expand global customer deployments, invest in safety architecture and product innovation, and pursue mergers and acquisitions.

The company plans to enhance its product offerings and is focused on entering new markets across Asia and Europe by mid-2026, further broadening its reach and impact in the healthcare sector.